CTNM — Contineum Therapeutics Share Price
Last trade - 00:00- $452.99m
- $335.08m
- $50.00m
- 28
- 30
- 68
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.09 | ||
| Price to Tang. Book | 4.09 | ||
| Price to Free Cashflow | 29.69 | ||
| Price to Sales | 9.56 | ||
| EV to EBITDA | 31.36 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.6% | ||
| Return on Equity | 32.7% | ||
| Operating Margin | 22.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 50 | n/a | 10 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The Company is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 7th, 2009
- Public Since
- April 5th, 2024
- No. of Shareholders
- 137
- No. of Employees
- 31
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 25,723,276
- Address
- 10578 Science Center Drive, Suite 200, SAN DIEGO, 92121
- Web
- https://www.contineum-tx.com/
- Phone
- +1 8583335280
- Auditors
- Ernst & Young LLP
Similar to CTNM
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 20:05 UTC, shares in Contineum Therapeutics are trading at $18.59. This share price information is delayed by 15 minutes.
Shares in Contineum Therapeutics last closed at $18.59 and the price had moved by over the past 365 days. In terms of relative price strength the Contineum Therapeutics share price has matched the S&P500 Index by over the past year.
The overall consensus recommendation for Contineum Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Contineum Therapeutics does not currently pay a dividend.
Contineum Therapeutics does not currently pay a dividend.
Contineum Therapeutics does not currently pay a dividend.
To buy shares in Contineum Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $18.59, shares in Contineum Therapeutics had a market capitalisation of $478.20m.
Here are the trading details for Contineum Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CTNM
Based on an overall assessment of its quality, value and momentum Contineum Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Contineum Therapeutics is $28.00. That is 50.62% above the last closing price of $18.59.
Analysts covering Contineum Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.83 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Contineum Therapeutics. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $18.59, shares in Contineum Therapeutics were trading +17.56% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Contineum Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $18.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Contineum Therapeutics' directors